-
2024-514746-36-00
1
2022-10-20
Selected tumor indications that are known to express FAP (Fibroblast a
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2024-515228-36-00
6
2022-08-18
Evaluation of the reduction of HPV infectivity and transmission before
-
2023-506247-42-00
3
2022-08-17
Relapsed/Refractory Multiple Myeloma
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2024-518242-24-00
5
2022-06-27
Chronic liver disease
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2024-512089-32-00
3
2022-03-28
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
-
2024-516893-31-01
5
2022-01-31
Allergic rhinoconjunctivitis due to exposure of house dust mites
-
2023-507568-38-00
1
2022-01-14
Metastatic or locally advanced tumors
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-504931-42-00
4
2021-04-06
Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2023-509847-29-00
7
2020-04-09
Advanced solid tumors